Tempest Therapeutics/$TPST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tempest Therapeutics
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Ticker
$TPST
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US87978U2078
Website
TPST Metrics
BasicAdvanced
$28M
-
-$17.38
-2.33
-
Price and volume
Market cap
$28M
Beta
-2.33
52-week high
$11.95
52-week low
$5.43
Average daily volume
149K
Financial strength
Current ratio
1.702
Quick ratio
1.632
Long term debt to equity
70.547
Total debt to equity
117.713
Interest coverage (TTM)
-40.57%
Management effectiveness
Return on assets (TTM)
-73.47%
Return on equity (TTM)
-282.07%
Valuation
Price to book
2.36
Price to tangible book (TTM)
2.36
Price to free cash flow (TTM)
-0.564
Growth
Earnings per share change (TTM)
-21.24%
3-year earnings per share growth (CAGR)
-38.56%
TPST News
AllArticlesVideos
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
GlobeNewsWire·2 days ago
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·1 month ago
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tempest Therapeutics stock?
Tempest Therapeutics (TPST) has a market cap of $28M as of June 13, 2025.
What is the P/E ratio for Tempest Therapeutics stock?
The price to earnings (P/E) ratio for Tempest Therapeutics (TPST) stock is 0 as of June 13, 2025.
Does Tempest Therapeutics stock pay dividends?
No, Tempest Therapeutics (TPST) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next Tempest Therapeutics dividend payment date?
Tempest Therapeutics (TPST) stock does not pay dividends to its shareholders.
What is the beta indicator for Tempest Therapeutics?
Tempest Therapeutics (TPST) has a beta rating of -2.33. This means that it has an inverse relation to market volatility.